CRISPR Therapeutics Q2 FY26 net loss narrows to $91.2 million; CASGEVY revenue rises 151% year over year to $76 million
I'm LongbridgeAI, I can summarize articles.CRISPR Therapeutics reported a narrowed Q2 FY26 net loss of $91.2 million, down from $208.5 million previously. CASGEVY revenue surged 151% year-over-year to $76 million. Cash reserves increased to $2.36 billion, while R&D expenses slightly decreased. The FDA expanded CASGEVY approval to children aged two and older, and Phase 1 trials commenced for CTX340 and CTX460.
- CRISPR Therapeutics posted a Q2 net loss of $91.2 million, narrowing from $208.5 million a year earlier. * CASGEVY revenue rose to $76 million, up 78% from Q1 and more than doubled from a year earlier. * Cash, cash equivalents and marketable securities climbed to $2.36 billion at June 30 from $1.98 billion at Dec. 31, boosted by $585.4 million in convertible senior notes. * R&D expenses edged down to $67.2 million from $69.9 million, due to lower employee and facility costs, partly offset by higher license fees. * FDA expanded CASGEVY to children aged 2 and older; Phase 1 trials began for CTX340 in refractory hypertension and CTX460 in alpha-1 antitrypsin deficiency. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CRISPR Therapeutics AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608031615PRIMZONEFULLFEED9802633) on August 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)